ArticleBMC musculoskeletal disorders2026
Denosumab combined with curettage after surgical dislocation of the hip in the treatment of giant cell tumors of bone in the femoral head and neck region: a single-center retrospective study.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiant cell tumor of bone (GCTB) occurring in the femoral head and neck region presents significant therapeutic challenges due to its complex anatomy and aggressive biological behavior. This study aimed to analyse the clinical outcomes of preoperative denosumab therapy combined with curettage after surgical dislocation of the hip in the treatment of GCTB at the femoral head and neck region.
methodsBetween 2016 and 2023, a total of 16 patients with GCTB in the femoral head and neck were treated at the authors' institution, of whom 14 eligible and included in the study (6 males/8 females, aged 17-35 years). All patients received three cycles of Denosumab therapy preoperatively, with treatment response monitored and therapeutic efficacy was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Subsequently, surgical dislocation of the hip combined with curettage of the lesion was performed. Regular postoperative follow-up was conducted to monitor for complications. Imaging studies were used performed to evaluate surgical site status, local recurrence, and distant metastasis. Limb function and hip joint function were assessed preoperatively and at 1 year postoperatively using the Musculoskeletal Tumor Society (MSTS) score and Harris Hip Score (HHS), respectively.
resultsAll 14 patients underwent a full course of preoperative denosumab therapy and underwent successful surgery, with a follow-up period of 24-50 months (mean 38.2 ± 9.0 months). No postoperative complications observed. Imaging revealed shrinkage of residual cavities, blurred boundaries, progressive bone sclerosis, and trabecular bone regeneration at the surgical site. Functional assessments demonstrated significant improvements in MSTS scores (preoperative: 22.3 ± 1.3 compared with postoperative: 27.6 ± 1.2, P <0.001) and HHS (preoperative: 72.4 ± 3.1 compared with postoperative: 88.9 ± 4.3, P <0.001). All patients achieved excellent functional status (MSTS >25, HHS >82) with preserved joint mechanics. Preoperative denosumab therapy achieved partial remission (PR) in 79% (11/14) and stable disease (SD) in 21% (3/14) patients according to RECIST 1.1 criteria. At final follow-up, no patients experienced local recurrence or metastatic progression.
conclusionsDenosumab treatment combined with curettage after surgical dislocation of the hip successfully treated GCTB in the femoral head and neck. The safety profile of denosumab as adjuvant therapy was favorable, with no drug-related complications observed. Postoperatively, native hip joints were preserved in all patients, with satisfactory functional outcomes and no evidence of tumor recurrence or metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.